These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37933369)

  • 1. The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis.
    Kotak S; Hassan W; Mehmood M; Kumar U; Sagreeka F; Karishma F; Kumari P; Pirya F; Saquib J; Iqbal A; Khan AA; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e46547. PubMed ID: 37933369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
    Xiong B; Nie D; Qian J; Yao Y; Yang G; Rong S; Zhu Q; Du Y; Jiang Y; Huang J
    ESC Heart Fail; 2021 Dec; 8(6):4852-4862. PubMed ID: 34716749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.
    Gao J; Zhang X; Xu M; Deng S; Chen X
    Front Pharmacol; 2023; 14():1237210. PubMed ID: 37601056
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
    BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sacubitril-valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis.
    Liu Y; Sun Y; Dai W
    Front Pharmacol; 2024; 15():1366035. PubMed ID: 38863978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Safety and Efficacy of the Early Use of Sacubitril/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.
    - A; Rashid M; Soto CJ; Virk GS; Mekowulu FC; Chaudhari SS; Batool S; Usama M
    Cureus; 2024 Feb; 16(2):e53784. PubMed ID: 38465175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Dargad RR; Prajapati MR; Dargad RR; Parekh JD
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis.
    Yang P; Han Y; Lian C; Wu X
    Front Cardiovasc Med; 2022; 9():988117. PubMed ID: 36093128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
    Zhang L; Yan K; Zhao H; Shou Y; Chen T; Chen J
    Ann Palliat Med; 2022 Mar; 11(3):1017-1027. PubMed ID: 35365031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
    Zhao J; Zeng Y; Shen X
    Clin Cardiol; 2021 Oct; 44(10):1354-1359. PubMed ID: 34464468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
    Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.
    Mohammad Z; Ahmad J; Sultan A; Penagaluri A; Morin D; Dominic P
    J Cardiovasc Electrophysiol; 2023 Apr; 34(4):1037-1042. PubMed ID: 36871177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    Huang Y; Zhang Y; Ma L; Zhou H; Fang C; Chen C
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):202-210. PubMed ID: 33929386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.
    Sohani ZN; Behlouli H; de Moura CS; Abrahamowicz M; Pilote L
    J Am Heart Assoc; 2023 Jul; 12(14):e028865. PubMed ID: 37421275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
    Yang HR; Xu XD; Shaikh AS; Zhou BT
    Ann Pharmacother; 2023 Aug; 57(8):907-917. PubMed ID: 36475871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Amin OA; Alaarag AF
    Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
    Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.